Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Rosenfeld, Ronit ^a   Marcus, Hadar ^a   Ben Arie, Einat ^a   Lachmi, Bat El ^a   Mechaly, Adva ^a   Reuveny, Shaul ^a   Gat, Orit ^a   Mazor, Ohad ^a   Ordentlich, Arie ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY 29; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 29; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY ISOLATION; ANTIBODY TITER; ARTICLE; BACTERIAL SPORE; BINDING KINETICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG ISOLATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; IMMUNOTHERAPY; LD 50; MALE; MOUSE; MYELOMA CELL; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; RAT; SURFACE PLASMON RESONANCE; ANIMAL; BACILLUS ANTHRACIS; CHO CELL; CRICETULUS; GENETICS; HAMSTER; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SERODIAGNOSIS;

ANIMALIA; BACILLUS ANTHRACIS; CAVIA;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; BACILLUS ANTHRACIS; BASE SEQUENCE; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; LETHAL DOSE 50; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; SPORES, BACTERIAL; SURFACE PLASMON RESONANCE;

EID: 67749137703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006351     Document Type: Article

References (33)

1. Atlas RM (2001) Bioterrorism before and after September 11. Crit Rev Microbiol 27: 355-379.
2. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, et al. (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8: 1019-1028.
3. Friedlander AM, Welkos SL, Ivins BE (2002) Anthrax vaccines. Curr Top Microbiol Immunol 271: 33-60.
4. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, et al. (1998) Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-1148.
5. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, et al. (1993) Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167: 1239-1243.
6. Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, et al. (2004) Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol 40: 71-74.
7. Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, et al. (2004) MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 42: 3626-3634.
8. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, et al. (2001) Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69: 2888-2893.
9. Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, et al. (2007) Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75: 5425-5433.
10. Brossier F, Levy M, Landier A, Lafaye P, Mock M (2004) Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72: 6313-6317.
11. Gubbins M, Berry J, Corbett C, Mogridge J, Yuan X, et al. (2006) Productionand characterization of neutralizing monoclonal antibodies that recognize an epitope in domain2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 47: 436-443.
12. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, et al. (2006) A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 74: 4149-4156.
13. Staats HF, Alam SM, Scearce RM, Kirwan SM, Zhang JX, et al. (2007) In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun 75: 5443-5452.
14. Zhang J, Xu J, Li G, Dong D, Song X, et al. (2006) The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem Biophys Res Commun 341: 1164-1171.
15. Cohen S, Mendelson I, Altboum Z, Kobiler D, Elhanany E, et al. (2000) Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 68: 4549-4558.
16. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of redefined specificity. Nature Biotechnology 256: 495-497.
17. Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC (1977) Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266: 550-552.
18. Benhar I, Reiter Y (2002) Phage display of single-chain antibody constructs. Curr Protoc Immunol Chapter 10: Unit 10 19B.
19. Singh Y, Chaudhary VK, Leppla SH (1989) A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem 264: 19103-19107.
20. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
21. Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, et al. (2006) Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 74: 5840-5847.
22. Chen Z, Moayeri M, Zhou YH, Leppla S, Emerson S, et al. (2006) Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 193: 625-633.
23. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, et al. (2007) High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51: 2758-2764.
24. Sawada-Hirai R, pharma A (2004) Guman anti-anthrax protective antigen neutralizing monoclonal. Journal of immune based therapies and vaccines 2.
25. Zhou B, Carney C, Janda KD (2008) Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem 16: 1903-1913.
26. Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, et al. (2002) Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 70: 544-560.
27. Tabrizi MA, Roskos LK (2007) Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 12: 540-547.
28. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, et al. (2005) The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38: 209-225.
29. Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, et al. (2007) Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75: 3414-3424.
30. Welkos S, Little S, Friedlander A, Fritz D, Fellows P (2001) The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685.
31. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, et al. (2009) Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine.
32. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. Baltimore: Williams and Wilkins.
33. Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, et al. (2004) Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun 72: 3471-3477.